According to the Complaint, the Plaintiff’s Decedent began taking Actos in 2010. Thereafter, she suffered from bladder cancer and subsequently died in October 2011.
New York, New York (PRWEB) December 15, 2012
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit alleging that Actos (pioglitazone) caused bladder cancer and wrongful death. The suit was filed on November 16th in the U.S. District Court for the Western District of Louisiana, Lafayette Division (Case No. 6:12-cv-2899). It is one of thousands of cases pending in the Actos multidistrict litigation as part of the In Re: Actos (Pioglitazone) Products Liability Litigation (MDL No. 6:11-md-2299). Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company have been named as Defendants.
According to the Complaint, the Plaintiff’s Decedent began taking Actos in 2010. Thereafter, she suffered from bladder cancer and subsequently died in October 2011. The suit alleges that the decedent’s wrongful death is a direct result of using Actos, which caused extensive pain and suffering, severe emotional distress, and substantially reduced the Decedent’s ability to enjoy life. The lawsuit also holds the Defendants responsible for failing to warn about the risks of Actos, and alleges that the Plaintiff’s Decedent would not have used the medication if the Defendants had properly disclosed the risks.
Actos was approved in 1999 as a Type-2 diabetes treatment. It is part of the thiazolidinedione (TZD) drug class, which also includes the medication Avandia. Last summer, the U.S. Food and Drug Administration (FDA) warned that using Actos for more than one year could significantly raise the risk of bladder cancer. At around the same time, use of the drug was suspended in France and Germany.
In August, a study published in the Journal of the National Cancer Institute found that using Actos and other TZDs long term could increase the chance of developing bladder cancer. This study echoed findings of previous research linking the drug to bladder cancer. In fact, a study published the month prior in the Canadian Medical Association Journal found that use of Actos was associated with a 22 percent increased risk of bladder cancer. In May, the British Medical Journal published a study suggesting that the risk of bladder cancer doubled in patients taking the drug for two years.
Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).
Parker Waichman LLP
Gary Falkowitz, Managing Attorney